Cancer Communications

Papers
(The H4-Index of Cancer Communications is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
493
Issue Information459
Issue Information285
Kindlin‐1 drives early steps of breast cancer metastasis273
Correction to “Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges”215
Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy199
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update188
Current status and perspectives of esophageal cancer: a comprehensive review185
Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study176
Defining and tracing subtypes of patient‐derived xenograft models in pancreatic ductal adenocarcinoma159
Loss of CDKN1B induces an age‐related clonal hematopoietic disorder via Notch2 activity dysregulation156
Fascin lysine 471 acetylation cooperates with serine 39 phosphorylation to inhibit actin‐bundling activity and tumor metastasis in esophageal squamous cell carcinoma147
Issue Information144
143
Single‐cell transcriptomics and epigenomics point to CD58‐CD2 interaction in controlling primary melanoma growth and immunity126
Nine‐fold variation of risk of advanced colorectal neoplasms according to smoking and polygenic risk score: Results from a cross‐sectional study in a large screening colonoscopy cohort124
121
Age‐specific effectiveness of primary human papillomavirus screening versus cytology in a cervical cancer screening program: a nationwide cross‐sectional study115
Issue Information114
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives114
Research trends of cancer metabolism: analysis from a Chinese perspective111
Nasopharyngeal carcinoma treatment paradigm after HK0501 – a potential way forward107
Single‐cell transcriptomics provides insights into the origin and immune microenvironment of cervical precancerous lesions101
100
Impact of pre‐existing cardiometabolic diseases on metastatic cancer stage at diagnosis: a prospective multinational cohort study98
Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with h92
89
Comparative single‐cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses86
Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5‐year update of the CinClare trial85
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer78
EXPRESSION OF CONCERN: Discovery of a Novel Viroid‐Like Circular RNA in Colorectal Cancer77
A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer76
Development and validation of an artificial intelligence model for predicting post‐transplant hepatocellular cancer recurrence70
Partial hepatectomy versus interventional treatment in patients with hepatitis B virus‐related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinica69
Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer67
Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial62
HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5‐WDR5‐dependent transcriptional program59
Multifunctional inorganic nanomaterials for cancer photoimmunotherapy54
Oral transforming growth factor‐beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti‐tumor immunity54
p38γ and p38δ as biomarkers in the interplay of colon cancer and inflammatory bowel diseases53
N6‐methyladenosine‐regulated exosome biogenesis orchestrates an immunosuppressive pre‐metastatic niche in gastric cancer peritoneal metastasis53
Issue Information51
Cover Image, Volume 45, Issue 650
50
Association of previously irradiated stable brain metastases with outcomes of atezolizumab‐treated non‐small cell lung cancer: A pooled analysis of individual patient data from three randomized trials50
Cover Image, Volume 42, Issue 148
48
Acquired RD3 loss regulates immune surveillance in high‐risk and therapy defying progressive neuroblastoma47
0.28763699531555